First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the

First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the

RUCONEST is Pharming Group's main revenue source today. This asset has already shown a sequential sa

Leiden, the Netherlands, September 29, 2026 : Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a g

If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who we

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immu

MAC Alpha Capital Management LP acquired a new position in Pharming Group N.V. Sponsored ADR (NASDAQ

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase

Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwi

Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), t

Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects

Ratio Petroleum Energy has raised its recommended offer for Pharos Energy (LSE:PHAR) to 32.8183p per

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder righ

Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (“Pharm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pharmin

Pharming Group shares fell 22% on July 30, 2026 after the Company reported a Q2 revenue decline and

A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026

NEW YORK--(BUSINESS WIRE)--A 22% single-session drop hit Pharming Group (PHAR) shares today after th

Leiden, the  Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHA

Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the

Pharming Group's legacy product RUCONEST posted a 10% year-over-year sales decline in Q2 2026 -- and

Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript

Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session.

U.S. stock futures rise, Meta shares drop 9.4%, Teladoc Health and Rentokil Initial fall after mixed

Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.00

Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.02 per share which met the analyst consensu

Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administr

Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.0

U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ:

Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other

For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 1

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.07) per share which missed the analyst conse

Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy ra

If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union fo

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and

First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (AP

Oppenheimer analyst Jeff Jones reiterates Pharming (NASDAQ:PHAR) with a Outperform and lowers the

 For 2026, the Company anticipates:Total revenues between US$405 million and US$425 million (8% to 1

Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.07 per share which beat the analyst consens

Highlights advancing clinical-stage pipeline, including two major value-creating programs for primar

FDA issued a CRL to Pharming's Joenja child use filing, citing dosing concerns in lower-weight k